Evidence map›Paper›PMID 39301599›Full record

ArticlePrimary health care research & development2024

Pharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care.

Onur Gultekin, Volkan Aydin, Dilara Bayram, Omer Atac, Ahmet Akici

Abstract read
In one paragraph

Article in Primary health care research & development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Onur GultekinDepartment of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey.ORCID 0000-0003-0527-0512
Volkan AydinDepartment of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0002-8511-6349
Dilara BayramDepartment of Pharmacology, School of Pharmacy, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.ORCID 0000-0001-7037-353X
Omer AtacDepartment of Public Health, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.ORCID 0000-0001-8984-9673
Ahmet AkiciDepartment of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey.ORCID 0000-0002-8593-0818

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of depression is gradually increasing worldwide with an increasing utilization of antidepressants. Nevertheless, despite their lower costs, generic-brand antidepressants were reported to be less prescribed. We aimed to examine the costs of reference- versus generic-brand antidepressant prescriptions in primary care practice.

methodsThis cross-sectional study included electronic prescriptions for adult patients that contained antidepressants (World Health Organization's Anatomical Therapeutic Chemical (ATC) code: N06A), which were generated by a systematically selected sample of primary care doctors (

findingsThe majority of the prescriptions were prescribed for women (71.8%), and the average age of the patients was 53.6 ± 16.2 years. In prescriptions with a depression-related indication (

conclusionsOur study highlighted the substantial pharmacoeconomic impact of generic-brand antidepressant prescribing, whose preference over reference-brands could reduce the cost of antidepressant medication treatment by 17.5% in primary care, which could be approximately doubled if the cheapest generic antidepressant had been prescribed.

Indexed as

Antidepressive AgentsDrugs, GenericPrimary Health CareAdultAgedCross-Sectional StudiesDepressionDrug CostsEconomics, PharmaceuticalFemaleHumansMaleMiddle AgedPractice Patterns, Physicians'TurkeyAntidepressive AgentsDrugs, Genericantidepressive agentsdrug utilizationgeneric drugspharmacoeconomicsprimary health care

Identifiers

PMID39301599
PMCPMC11464804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.